VENOUS THROMBOEMBOLISM VTE encompasses both deep vein thrombosis (DVT), blood clots in the deep veins of the body, and pulmonary embolism (PE), which occurs when DVT travels to the lungs. VTE is a major cause of death and disability worldwide. Despite its prevalence and severity, VTE is underdiagnosed and undertreated.

Since 2013, Inari Medical has revolutionized the standard of care for venous disease with innovative, purpose-built devices. Inari’s mission to treat and transform the lives of patients suffering from venous disease extends into multiple programs specifically designed to advance awareness and treatment of VTE.

Over 30,000 patients treated

Leading clinical data

Comprehensive VTE physician education

Customized VTE program development

A non-standardized approach to VTE patient care leads to a fragmented patient pathway resulting in inconsistent triage, treatment and follow up.


The VTE Excellence™ approach to patient care was developed in partnership with venous disease experts who have successfully solved existing fragmented patient pathways and improved VTE clinical outcomes. Like pathways developed to improve patient outcomes for myocardial infarction (MI) and stroke, VTE Excellence™ ensures that patients who should receive interventional consultation for venous disease are not missed.


Inari Medical is pioneering the treatment of venous disease through long-term, strategic partnerships through the Inari Solutions Group (ISG). ISG partners with health systems and physicians to improve patient pathways, clinical outcomes, health economics and disease awareness.

Patient Pathway

Customized processes to appropriately identify and treat patients that improve: 

  •   Triage
  •   Treatment
  •   Follow up

Health Economics

Comprehensive support to provide tailored assistance with:

  •   Resource efficiencies
  •   Reimbursement
  •   Coding and billing support

Clinical Outcomes

Access to purpose-built medical devices and training support designed to improve:

  • Mortality
  • Resource utilization
  • Readmission and LOS

Disease Awareness

Tools to expand understanding of disease and advanced therapy options, including:

  •   Media
  •   Patient testimonials 
  •   In-reach and out-reach

1. Centers for Disease Control and Prevention. Venous Thromboembolism (Blood Clots). Data & Statistics.

2. Secemsky E, et al. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. Journal of American Heart Association. 2018.

3. Lacey MJ, et al. Prospective Experience of Pulmonary Embolism Management and Outcomes. J Invasive Cardiol. 2021

4. Key N, et al. Current Treatment of Venous Thromboembolism. Arterioscler Thromb Vasc Biol. March 2010.

5. Rokosh R, et al. High Incidence of patients lost to follow-up after venous thromboembolism diagnosis— Identifying an unmet need for targeted transition of care. Vascular. 2021.